bioAffinity Technologies, Inc. BIAF
2.93 USD -0.26 (-8.15%)
At closeNov 5, 2026, 5:09 AM EST
2.94 +0.01 +0.24%
Pre-market · Nov 5, 5:09 AM ET
2.93 Day range 3.22
2.66 52-week range 80.70
- YTD
- -83.45%
- 1 year
- -91.00%
News
businesswire.com bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies will share benefits of CyPath Lung with North Carolina lung cancer patient advocacy and healthcare community at Nov. 5 event.
benzinga.com bioAffinity Technologies To Present New Data On Sputum-Based Tests In Development To Characterize Lung Inflammation And Detect Multiple Protein Biomarkers Of Lung Inflammation At CHEST 2026 Findings report on ability to measure cellular and soluble inflammatory protein biomarkers in sputum, including biologic drug targetsCompany advances research and development in diagnostic tests for…
benzinga.com bioAffinity Technologies Commences ~$4M Offering Of Common Stock At $6.122 Per Share bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that…
benzinga.com bioAffinity Technologies Announces 100% Increase In Sales For Its CyPath Lung Test For Lung Cancer bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that…